38
Participants
Start Date
April 25, 2013
Primary Completion Date
February 19, 2016
Study Completion Date
February 7, 2017
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
"Step 1: From entry through week 12, the participants received no study treatment. From week 12 through week 60, the participants received one fixed dose combination emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) tablet daily.~Step 2 (Optional): From week 60 through week 108, the participants either received one FTC/RPV/TDF tablet daily or no study treatment."
Bronx-Lebanon Hosp. Ctr. CRS (31469), The Bronx
University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787), Rochester
Pitt CRS (1001), Pittsburgh
Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia
Whitman Walker Health CRS (31791), Washington D.C.
IHV Baltimore Treatment CRS (4651), Baltimore
Moses H. Cone Memorial Hospital CRS (3203), Greensboro
Unc Aids Crs (3201), Chapel Hill
The Ponce de Leon Ctr. CRS (5802), Atlanta
31788 Alabama CRS, Birmingham
Metro Health CRS (2503), Cleveland
University of Cincinnati CRS (2401), Cincinnati
Northwestern University CRS (2701), Chicago
Rush Univ. Med. Ctr. ACTG CRS (2702), Chicago
Houston AIDS Research Team CRS (31473), Houston
801 University of California, San Francisco HIV/AIDS CRS, San Francisco
Massachusetts General Hospital ACTG CRS (101), Boston
Brigham and Women's Hosp. ACTG CRS (107), Boston
The Miriam Hosp. ACTG CRS (2951), Providence
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
NETWORK